OncoMatch/Clinical Trials/NCT06092957
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
Is NCT06092957 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Cisplatin-based induction chemotherapy and Full course of PD-1/PD-L1 blockades for nasopharyngeal carcinoma.
Treatment: Cisplatin-based induction chemotherapy · Full course of PD-1/PD-L1 blockades · Concurrent Chemotherapy — This prospective trial aims to enroll patients with high-risk stage III-IVA (AJCC 8th, except T3N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC). Under the condition of full course of PD-1/PD-L1 blockades, patients who achieved both radiological and biological complete response after 3 cycles of platinum-based chemotherapy plus PD-1/PD-L1 blockades will be randomized in a 1:1:1 ratio to receive reduced-dose radiotherapy (60Gy/30F) alone or reduced-dose radiotherapy plus concurrent chemotherapy or standard dose radiotherapy (70Gy/33F) with concurrent chemotherapy. To solve the urgent problem of whether patients with high-risk advanced nasopharyngeal carcinoma are suitable for downgrade treatment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV DNA load = 0 copies/mL (or lower than the test line) (0 copies/mL (or lower than the test line))
EBV DNA load =0 copies/mL (or lower than the test line) after 3 cycles of induction therapy
Disease stage
Required: Stage III, IVA
Excluded: Stage T3N0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy plus immunotherapy — induction
after 3 cycles of induction therapy of platinum-based chemotherapy plus immunotherapy
Cannot have received: chemotherapy
Exception: induction therapy as specified
Patients have received prior chemotherapy, immunotherapy, targeted therapy, or surgery (other than diagnostic treatment)
Cannot have received: immunotherapy
Exception: induction therapy as specified
Patients have received prior chemotherapy, immunotherapy, targeted therapy, or surgery (other than diagnostic treatment)
Cannot have received: targeted therapy
Patients have received prior chemotherapy, immunotherapy, targeted therapy, or surgery (other than diagnostic treatment)
Cannot have received: surgery
Exception: diagnostic treatment
Patients have received prior chemotherapy, immunotherapy, targeted therapy, or surgery (other than diagnostic treatment)
Cannot have received: anti-PD-1 antibody
Subjects who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-PD-L1 antibody
Subjects who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-CTLA-4 antibody
Subjects who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Cannot have received: anti-angiogenic drugs
Subjects who underwent anti-PD-1 /PD-L1 antibody or anti-CTLA-4 antibody (or any other antibody acting on T cell synergistic stimulation or checkpoint pathway) and anti-angiogenic drugs
Lab requirements
Blood counts
neutrocyte count≥4×10e9/L, hemoglobin ≥90g/L, platelet count ≥100×10e9/L
Kidney function
creatinine clearance rate ≥ 60 ml/min or creatinine ≤ 1.5×ULN
Liver function
ALT/AST ≤2.5×ULN, bilirubin ≤2.5×ULN
Adequate marrow function: neutrocyte count≥4×10e9/L, hemoglobin ≥90g/L and platelet count ≥100×10e9/L. Adequate liver and kidney function: ALT/AST ≤2.5×ULN, bilirubin ≤2.5×ULN; creatinine clearance rate ≥ 60 ml/min or creatinine ≤ 1.5×ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06092957 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EBV?
Yes, EBV DNA load = 0 copies/mL (or lower than the test line) is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages